KLFII is an Epigenetic Mediator of DRD2/Dopaminergic Signaling in Endometriosis

Elliott G Richards, Ye Zheng, Chandra C Shenoy, Alessandra J Ainsworth, Abigail A Delaney, Tiffanny L Jones, T.L. Jones, Zaraq Khan, Gaurang S Daftary
Reproductive sciences (Thousand Oaks, Calif.) · 2017 · vol. 24(8) , pp. 1129–1138 · doi:10.1177/1933719117698582 · PMID:28372535 · W2605048412
article OA: closed CC0 ⤵ 9 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

This study investigated how transcription factor KLF11 regulates DRD2 expression in endometriosis, finding KLF11 binding activates the DRD2 promoter and gene expression, with its loss associated with fibrosis and decreased DRD2 in a mouse model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

The study investigated how the transcription factor KLFII regulates dopamine receptor 2 (DRD2) by examining KLFII binding/activation of the DRD2 promoter in eutopic and ectopic endometrial cell lines and in a surgically induced murine model of endometriosis. KLFII-driven promoter activation of DRD2 was conserved across species and corresponded to increased DRD2 expression in an endometrial cell line and in primary endometriotic cells, while Klf11 knockout animals showed progressive fibrosis with decreased Drd2 expression. The authors note a mechanistic limitation: activation of DRD2 by KLFII could not be fully explained by loss of epigenetic corepressor binding and likely involves selective coactivator recruitment, which was not identified in this work. This paper is centrally about endometriosis — it defines KLFII as an epigenetic regulator of DRD2/dopaminergic signaling in endometriotic lesions and models.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

DNA-Binding Proteins Dopamine Endometriosis Epigenesis, Genetic Receptors, Dopamine D2 Signal Transduction Transcription Factors Animals Apoptosis Regulatory Proteins Cell Line Disease Models, Animal DNA-Binding Proteins DNA-Binding Proteins Dopamine Endometriosis Female Mice Mice, Knockout Receptors, Dopamine D2 Repressor Proteins

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (37)

Cited by (9)

Source provenance

europepmc
last seen: 2026-06-12T06:13:51.797165+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:31.759405+00:00
License: CC0 · commercial use OK